TherapeuticsMD Announces Third Quarter 2026 Financial Results
Business Wire•13/11/2026•16:05 ET
0
Key Highlights
- ➤License revenue $1.3 million, up 60.6% year over year
- ➤Net income from continuing operations $501 thousand, versus $50 thousand
- ➤IMVEXXY 2026 sales milestone achieved; revenue recognition due in Q4 2026
- ➤Cash and cash equivalents totaled $10.4 million at September 30
- ➤TherapeuticsMD continues evaluating acquisitions, mergers, asset sales, or other strategic transactions
TherapeuticsMD Announces Third Quarter 2026 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2026.
Get started
Create a free account to read the full story.